MENT (Trestolone)

MENT — 7-alpha-methyl-19-nortestosterone, known as Trestolone — is a synthetic 19-nortestosterone derivative originally developed for male contraception and hormone replacement therapy. The 7-alpha methyl modification makes Trestolone approximately 10 times more potent than testosterone at the androgen receptor while also conferring resistance to 5-alpha reductase metabolism, meaning it does not convert to DHT or its analogs. Despite being a 19-nor compound, Trestolone aromatizes to 7-alpha-methylestradiol, a potent estrogen — a critical distinction from nandrolone, which aromatizes minimally. MENT is arguably the most pharmacologically potent anabolic compound available outside of trenbolone, but with a fundamentally different side-effect and metabolic profile.

Trestolone's mechanism of action involves extraordinarily high-affinity androgen receptor binding — binding studies demonstrate approximately 2.5 times the affinity of DHT and 10 times that of testosterone. This translates to profound anabolic signaling at doses far lower than traditional testosterone protocols. MENT also suppresses gonadotropins (LH and FSH) more completely than testosterone, which is the basis for its contraceptive applications but also means that endogenous recovery after cessation requires careful PCT planning. The compound drives protein synthesis, nitrogen retention, and satellite cell activation at rates that produce visible physique changes within days of reaching therapeutic serum levels.

MENT produces rapid, dramatic increases in lean body mass, strength, and muscle fullness. Researchers consistently describe a "3D" quality to the muscle — a combination of intracellular volumization and genuine contractile protein accrual that distinguishes MENT gains from the water-mediated fullness of compounds like Dianabol. The strength increases are equally pronounced, often appearing within the first week of administration. MENT is genuinely a next-generation compound: it offers the mass-building potency of trenbolone with a side-effect profile that, while not mild, is more manageable for most researchers — no insomnia, no night sweats, no cardiovascular endurance impairment.

This compound is for experienced researchers with established bloodwork baselines and competent ancillary management. The significant aromatization to 7-alpha-methylestradiol demands vigilant estrogen control — standard AI dosing protocols based on testosterone cycles may be insufficient, and titration based on symptom assessment and bloodwork is essential. Researchers should also understand that MENT's extreme gonadotropin suppression makes PCT recovery more challenging than with testosterone alone. It is not a beginner compound, but for researchers ready for it, MENT represents the cutting edge of anabolic pharmacology.

Trestolone Acetate has a half-life of approximately 40 minutes to 2 hours in its unesterified form; the acetate ester extends this to roughly 1-2 days. Daily or every-other-day injection is standard. Effective doses are low relative to testosterone — 10-50mg/day (70-350mg/week) is the typical research range, reflecting the compound's extreme potency per milligram. MENT can replace testosterone as the androgenic base in a cycle (it provides full androgenic support), though some researchers prefer to run a low-dose testosterone alongside it for the neurosteroid benefits of DHT conversion. Aromatase inhibitor dosing should be established early and adjusted frequently. PCT after MENT requires aggressive SERM therapy (Nolvadex + Clomid) and potentially HCG, given the depth of gonadotropin suppression.